Results 71 to 80 of about 5,281 (192)

Vaccines with the MF59 Adjuvant Do Not Stimulate Antibody Responses against Squalene [PDF]

Clinical and Vaccine Immunology, 2006
ABSTRACT Squalene is a naturally occurring oil which has been used in the development of vaccine adjuvants, such as the oil-in-water emulsion MF59. In past years, by use of noncontrolled and nonvalidated assays, a claim was made that antisqualene antibodies were detectable in the sera of individuals with the so-called Gulf War syndrome. Using
Giuseppe, Del Giudice, Elena, Fragapane, Roberto, Bugarini, Maninder, Hora, Thomas, Henriksson, Emanuela, Palla, Derek, O'hagan, John, Donnelly, Rino, Rappuoli, Audino, Podda   +9 more
openaire   +2 more sources

Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of age [PDF]

, 2014
Background: Vaccines against pandemic A/H1N1 influenza should provide protective immunity in children, because they are at greater risk of disease than adults.
Rivera, L., Leroux-Roels, G., Abarca Villaseca, Katia, Arora, A., Knuf, M., Rumke, H., Pedotti, P., Lattanzi, M., Lattanzi, Maria, Pedotti, Paola, Kieninger-Baum, Dorothee, Knuf, Markus, Della Cioppa, Giovanni, Rivera, Luis, Abarca, Katia, Leroux-Roels, Geert, Rümke, Hans C, Arora, Ashwani   +17 more
core   +1 more source

The cytomegalovirus gB/MF59 vaccine candidate induces antibodies against an antigenic domain controlling cell-to-cell spread

Nature Communications, 2023
A gB/MF59 vaccine candidate for human cytomegalovirus (HCMV) provided partial protection in organ transplant patients. Here, the authors identify antibody responses in trial participants that target virally infected cells to control cell-to-cell spread ...
A. C. Gomes, I. A. Baraniak, A. Lankina, Z. Moulder, P. Holenya, C. Atkinson, G. Tang, T. Mahungu, F. Kern, P. D. Griffiths, M. B. Reeves   +10 more
doaj   +1 more source

The Squalene Oil‐in‐Water Nanoemulsion Vaccine Carrier AddaVax Potentiates TLR‐Induced B‐Cell Responses

Cytometry Part A, Volume 109, Issue 3, Page 180-191, March 2026.
ABSTRACT For vaccination, the mechanisms of action of antigens and of immunostimulatory pathogen‐associated molecular pattern (PAMP) adjuvants are better understood than the roles of the depot, carrier, and other formulation‐related influences. Here, we carried out cytometric studies of vaccine formulations and the effect of adjuvant formulations on B ...
Egest J. Pone, Jiin Felgner, Jenny Hernandez‐Davies, D. Huw Davies   +3 more
wiley   +1 more source

Safety and Immunogenicity of Nonadjuvanted and MF59-Adjuvanted Influenza A/H9N2 Vaccine Preparations [PDF]

Clinical Infectious Diseases, 2006
Influenza A/H9N2 viruses can infect humans and are considered to be a pandemic threat. Effective vaccines are needed for these and other avian influenza viruses.We performed a phase I, randomized, double-blind trial to evaluate the safety and immunogenicity of a 2-dose schedule (administered on days 0 and 28) of 4 dose levels (3.75, 7.5, 15, and 30 ...
Robert L, Atmar, Wendy A, Keitel, Shital M, Patel, Jacqueline M, Katz, Dewei, She, Hana, El Sahly, Justine, Pompey, Thomas R, Cate, Robert B, Couch   +8 more
openaire   +2 more sources

Rapid and frequent induction of protective immunity exceeding UK recommendations for healthcare settings by MF59-adjuvated hepatitis B vaccine.

, 2020
The ability of three doses of a novel MF59-adjuvanted hepatitis B virus (HBV) vaccine containing surface and pre-S2 antigens given at 0, 1, and 6 months to induce levels of HBV surface antibody (sAb) > or = 100 mIU/ml was compared with a UK licensed alum-
Eiden, JE, Langenberg, AG, Lewis, DJ, Goilav, C, Suggett, F, Griffin, GE   +5 more
core  

Varicella Zoster Virus Infection: Clinical Features, Molecular Pathogenesis, Treatment, and Prevention

MedComm, Volume 7, Issue 3, March 2026.
This review focuses on the clinical features, molecular mechanisms, treatment methods, and preventive measures of the VZV, with the aim of providing a theoretical basis for the development of new treatment and prevention methods for HZ. ABSTRACT Varicella zoster virus (VZV) is a ubiquitous human herpesvirus that establishes lifelong latency and causes ...
Lei Peng, Honghao Song, Tianying Li, Yuqing Ma, Chen Yan, Yuhan Cao, Kaiqiang Sun, Chaofeng Han, Hongbin Yuan   +8 more
wiley   +1 more source

A caprine herpesvirus 1 vaccine adjuvanted with MF59™ protects against vaginal infection and interferes with the establishment of latency in goats.

PLoS ONE, 2012
The immunogenicity and the efficacy of a beta-propiolactone-inactivated caprine herpesvirus 1 (CpHV-1) vaccine adjuvanted with MF59™ were tested in goats.
Mariarosaria Marinaro, Giovanni Rezza, Giuseppe Del Giudice, Valeriana Colao, Elvira Tarsitano, Michele Camero, Michele Losurdo, Canio Buonavoglia, Maria Tempesta   +8 more
doaj   +1 more source

Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59® adjuvant: results from a dose-finding clinical trial in older adults

, 2012
Background: MF59-adjuvanted influenza vaccines have superior immunogenicity in older adults compared with non-adjuvanted vaccines. We assessed whether changing formulation (i.e., increasing H3N2 antigen or decreasing the quantity of adjuvant) of the ...
Nicolay, Uwe, Del Giudice, Giuseppe, Groth, Nicola, Leroux-Roels, Geert, Galli, Grazia, Della Cioppa, Giovanni, Clement, Frédéric, Castellino, Flora, Lindert, Kelly   +8 more
core   +1 more source

Cumulative clinical experience with MF59-adjuvanted trivalent seasonal influenza vaccine in young children

International Journal of Infectious Diseases, 2019
Objective: To demonstrate the potential of an MF59-adjuvanted inactivated trivalent seasonal influenza vaccine (aIIV3; Fluad™) to improve the immune response in young children, we review the immunogenicity, efficacy, and safety/tolerability of aIIV3 from
Sanjay S. Patel, Svetlana Bizjajeva, Kelly Lindert, Esther Heijnen, Janine Oberye   +4 more
doaj   +1 more source